Literature DB >> 27408347

Therapy Related Acute Myeloid Leukemia with t(8;16) Mimicking Acute Promyelocytic Leukemia.

Taher Chharchhodawala1, Smeeta Gajendra1, Priya Tiwari2, Ajay Gogia2, Ritu Gupta1.   

Abstract

Acute myeloid leukemia (AML) with t(8;16)(p11;q13) is a distinct clinical and morphological entity with poor prognosis, which is characterized by a high frequency of extramedullary involvement, most commonly leukemia cutis; association with therapy related AML; frequent coagulopathy and morphologic features overlapping acute promyelocytic leukemia(APL). Herein, we present a case of 47 year-old post-menopausal woman developing secondary AML with t(8;16)(p11;q13) after 1 year of completion of therapy for breast carcinoma. Blasts were granulated with few showing clefted nucleus resembling promyelocytes and immnuophenotyping showed high side scatter with MPO positivity and CD 34 and HLA-DR negativity. In view of promyelocyte like morphology and immunophenotyping of blasts, possibility of APL was considered but, reverse transcription polymerase chain reaction (RT-PCR) for PML-RARα fusion transcript came out to be negative. Conventional cytogenetics showed t(8;16)(p11;q13). So, we should keep possibility of t(8;16) (p11;q13) in therapy related acute myeloid leukemia in patient showing clinical and morphological features of acute promyelocytic leukemia.

Entities:  

Keywords:  Secondary AML; Therapy related AML; t(8;16)

Year:  2015        PMID: 27408347      PMCID: PMC4925497          DOI: 10.1007/s12288-015-0527-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  8 in total

1.  Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin's lymphoma.

Authors:  P Bernasconi; E Orlandi; P Cavigliano; S Calatroni; M Boni; C Astori; G Pagnucco; S Giglio; M Caresana; M Lazzarino; C Bernasconi
Journal:  Haematologica       Date:  2000-10       Impact factor: 9.941

Review 2.  Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review.

Authors:  Francesco Marchesi; Ombretta Annibali; Elisabetta Cerchiara; Maria Cristina Tirindelli; Giuseppe Avvisati
Journal:  Crit Rev Oncol Hematol       Date:  2010-12-03       Impact factor: 6.312

3.  The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia.

Authors:  Tomoo Daifu; Itaru Kato; Kagehiro Kozuki; Katsutsugu Umeda; Hidefumi Hiramatsu; Ken-Ichiro Watanabe; Ichiro Kamiya; Tomohiko Taki; Tatsutoshi Nakahata; Toshio Heike; Souichi Adachi
Journal:  J Pediatr Hematol Oncol       Date:  2014-07       Impact factor: 1.289

4.  Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation.

Authors:  María Rozman; Mireia Camós; Dolors Colomer; Neus Villamor; Jordi Esteve; Dolors Costa; Ana Carrió; Marta Aymerich; Josep Lluis Aguilar; Alícia Domingo; Francesc Solé; Federico Gomis; Lourdes Florensa; Emili Montserrat; Elias Campo
Journal:  Genes Chromosomes Cancer       Date:  2004-06       Impact factor: 5.006

5.  Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique.

Authors:  C Gervais; A Murati; C Helias; S Struski; A Eischen; E Lippert; I Tigaud; D Penther; C Bastard; F Mugneret; B Poppe; F Speleman; P Talmant; J VanDen Akker; L Baranger; C Barin; I Luquet; N Nadal; F Nguyen-Khac; O Maarek; C Herens; D Sainty; G Flandrin; D Birnbaum; M-J Mozziconacci; M Lessard
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

6.  Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.

Authors:  Adi Diab; Lynette Zickl; Omar Abdel-Wahab; Suresh Jhanwar; Manjit A Gulam; Katherine S Panageas; Jay P Patel; Joseph Jurcic; Peter Maslak; Elisabeth Paietta; James K Mangan; Martin Carroll; Hugo F Fernandez; Julie Teruya-Feldstein; Selina M Luger; Dan Douer; Mark R Litzow; Hillard M Lazarus; Jacob M Rowe; Ross L Levine; Martin S Tallman
Journal:  Leuk Res       Date:  2012-10-24       Impact factor: 3.156

7.  Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.

Authors:  Eva A Coenen; C Michel Zwaan; Dirk Reinhardt; Christine J Harrison; Oskar A Haas; Valerie de Haas; Vladimir Mihál; Barbara De Moerloose; Marta Jeison; Jeffrey E Rubnitz; Daisuke Tomizawa; Donna Johnston; Todd A Alonzo; Henrik Hasle; Anne Auvrignon; Michael Dworzak; Andrea Pession; Vincent H J van der Velden; John Swansbury; Kit-fai Wong; Kiminori Terui; Sureyya Savasan; Mark Winstanley; Goda Vaitkeviciene; Martin Zimmermann; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2013-08-23       Impact factor: 22.113

8.  AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.

Authors:  T Haferlach; A Kohlmann; H-U Klein; C Ruckert; M Dugas; P M Williams; W Kern; S Schnittger; U Bacher; H Löffler; C Haferlach
Journal:  Leukemia       Date:  2009-02-05       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.